Contact
en
CN

Build or Buy? A Guide to Biometrics Resourcing

Build or Buy? A Guide to Biometrics Resourcing
Table of Content [Hide]

    build or buy a guide to biometrics resourcing


    The Strategic Crossroads Every Biotech and Pharma Company Faces

    In today's increasingly complex market, where 80% of clinical trials face delays and competition is intensifying, the question isn't whether you need robust biometrics capabilities—it's whether you should build them in-house or partner with specialized experts. According to recent industry analysis, pharma leaders are now exploring fundamental changes to their operating models, with simplification and digital transformation at the forefront.


    The True Cost Equation

    Building In-House Biometrics Teams:

    ●  Average annual cost per senior statistician: $150,000-$200,000

    ●  Average annual cost per experienced programmer: $120,000-$160,000

    ●  Infrastructure and technology investments: $500,000+ initially

    ●  6-12 months average recruitment time for specialized talent

    ●  20-30% turnover rate in highly competitive markets


    Partnering with External Experts:

    ●  Immediate access to specialized expertise

    ●  Flexible scaling based on project demands

    ●  Zero recruitment, training, or retention costs

    ●  Access to proven systems and processes

    ●  Accelerated timelines with experienced teams


    Decision Factors at Different Company Stages

    Early-Stage Biotech

    Key Challenges:

    ● Limited capital resources

    ● Focus on scientific proof-of-concept

    ● Unpredictable workflow demands

    ● Limited regulatory experience

    ● Building distinctive capabilities in competitive therapeutic areas


    Strategic Recommendation: External partnerships provide immediate expertise without fixed overhead, allowing you to invest capital in your core science while accessing senior-level biometrics guidance only when needed. This aligns with industry trends where companies must identify which capabilities are essential for their future portfolios and distinguish between areas requiring excellence versus those meeting industry standards.


    Mid-Size Companies

    Key Challenges:

    ● Multiple simultaneous clinical programs

    ● Growing regulatory interactions

    ● Balancing headcount with variable workloads

    ● Building institutional knowledge

    Strategic Recommendation: Hybrid models excel here—build a small core team of strategic leads while leveraging external partners for execution and specialized expertise.


    Large Pharma

    Key Challenges:

    ● Global coordination

    ● Consistent quality across programs

    ● Integration of legacy systems

    ● Peak resource management

    Strategic Recommendation: Maintain strategic oversight internally while leveraging specialized external partners for functional support, overflow capacity, and geographical coverage.


    The Hidden Costs of Building vs. Buying

    Factor

    Build Implications

    Buy Advantages

    Technology

    Ongoing investments in software, hardware, and validation

    Access to validated systems with no capital investment

    Training

    Continuous investment in staff development

    Always-current expertise included

    Turnover

    Knowledge gaps and recruitment cycles

    Continuity of service guaranteed

    Scalability

    Fixed capacity regardless of pipeline changes

    On-demand resources aligned to actual needs

    Focus

    Management attention diverted to operational issues

    Leadership focused on strategic decisions

    Digital Transformation

    Requires dedicated AI/digital talent acquisition

    Immediate access to advanced digital capabilities

    Organizational Complexity

    Creates additional management layers

    Streamlined structure with focused expertise

    Process Efficiency

    Risk of complex, time-consuming processes

    Proven workflows that eliminate bottlenecks


    The Simplification Advantage in Biometrics

    Recent industry research by Mckinsey  reveals that pharmaceutical companies are actively simplifying their operations, with organizational streamlining efforts projected to yield over $7 billion in cost savings. Here's how simplification principles apply to biometrics resourcing:

    1. Accelerated Decision-Making: Two-thirds of pharma leaders rank speeding up decision-making as crucial for simplification

    2. Reduced Manual Workloads: Streamlining processes can cut time requirements by 3-15%, freeing resources for high-value activities


    Success Stories: The Hybrid Approach

    A strategic combination often yields the best results:

    Case Study: Emerging Biotech Success By maintaining a small internal biometrics leadership team while partnering with our global experts for execution, one emerging biotech saved $30M over ten years while successfully achieving 3 FDA approvals.

    Case Study: Mid-Size Pharma Flexibility When facing an unexpected surge in development activities, a mid-size pharma leveraged our team to double their biometrics capacity within 30 days—without adding permanent headcount.


    Four Strategic Paths to Optimize Your Biometrics Model

    Based on leading industry research, consider these four strategic approaches when deciding between building or partnering for biometrics capabilities:

    1. Identify Distinctive Capabilities

    ● Evaluate which biometrics skills are truly distinctive to your strategy

    ● Determine where excellence is essential versus where industry standards suffice

    ● Consider that fewer than a third of life sciences leaders believe their organizations currently possess adequate capabilities for future portfolios


    2. Simplify Organizational Structure

    ● Avoid complex matrix organizations that hinder agility

    ● Reduce redundant layers between global and local operations

    ● Only one in five industry leaders believe their current models enable timely decision-making


    3. Streamline Processes

    ● Target burdensome processes like financial planning and performance management

    ● Potential time savings of 3-15% through process optimization

    ● Redesign routine activities to eliminate bottlenecks


    4. Embrace Digital-First Strategies

    ● Integrate AI and automation to reduce manual workloads

    ● One company's digital adoption generated hundreds of millions in savings

    ● Streamlined analytics can deliver 10-15% uplift in operations


    Next Steps: Your Personalized Assessment

    The optimal resourcing model depends on your specific situation. Our team of biometrics experts offers complimentary consultations to help you determine the right approach for your clinical development needs. We'll assess your protocol, analysis plan, biometrics resources, and vendor gaps—at no cost.


    Contact: Suling Zhang, VP of International Operations and Business Development
    Email: suling.zhang@gcp-clinplus.com
    Phone: +1 609-255-3581


    About GCP ClinPlus

    With 22 years of experience, 2,200+ successful projects, and 160+ NDA approvals from FDA, NMPA, and EMA, GCP ClinPlus offers unparalleled biometrics expertise. Our US team brings 30+ years of global regulatory experience to every engagement.

    References

    CRO Solutions You May Be Interested In

    Latest Articles from GCP ClinPlus

    Why Global Biotechs are Turning to China for Clinical Trials: The Speed, Quality, and Cost Advantage
    Celebrating Another Milestone: Onradivir Tablets Approved
    China Speed in CGT: From IND to NDA in 20 Months
    2005 Eastpark Blvd., Cranbury, New Jersey, USA, 08540
    Headquarters Address:
    Building 1, Hanwei International Zone 3, 186 South Fourth Ring West Road, Fengtai District, Beijing
    Tel: +86 400-1006-531
    global@GCP-ClinPlus.com +1 609-2553581
    We use cookies on this site, including third party cookies, to delivery experiennce for you. cookie policy to learn more.
    Reject Accept Cookies